HOME > TOP STORIES
TOP STORIES
-
REGULATORY DPP Confirms Plan to Urge 4 Ministers to Scrap Off-Year Price Revisions
November 28, 2024
-
COMMENTARY MOF Stands Pat with Off-Year Revisions despite Change in Politics, Does this Hint at Govt’s Reform Directions?
November 27, 2024
-
BUSINESS Shionogi Chided for Violating Promotion Guidelines with Actair
November 27, 2024
-
REGULATORY Japan Gets Down to the Business of Solving Drug Loss, New Scheme Begins with 78 Meds
November 26, 2024
-
REGULATORY Japan’s New Economic Package Covers Pharma-Related Steps, but Not Repeal of Off-Year Revisions
November 25, 2024
-
REGULATORY Pharma Renews Call for Abolishing Off-Year Revisions, but MHLW Stays Put with Honebuto
November 22, 2024
-
BUSINESS Genmab Japan to Expand into Solid Tumors, Boost Focus on Gyn/Onc: Chief
November 22, 2024
-
REGULATORY 3 Parties Reach Deal on Economic Plan, Off-Year “Abolition” Not Spelled Out
November 21, 2024
-
BUSINESS 25 Japan Drug Makers See 50% Growth in Operating Profit on FX, Unprofitability Re-Pricing
November 20, 2024
-
REGULATORY DPP Leader Poised to Urge 4 Ministers to Abolish Off-Year Revisions
November 20, 2024
-
ORGANIZATION Chuikyo Payer Rep Touts Necessity of FY2025 Off-Year Price Revision
November 19, 2024
-
REGULATORY Qalsody, Zepbound, Zeposia Up for Advisory Panel Review on Dec. 2
November 19, 2024
-
REGULATORY Pediatric Forms of Jakavi, More Drugs to Get Listing; Eylea Biosimilar Not on Roster
November 19, 2024
-
REGULATORY DPP Prods Ruling Camp to Be More Specific on Off-Year Revision in Economic Plan
November 19, 2024
-
BUSINESS Pfizer Japan Taps COO Hiroo Igarashi as New Skipper
November 18, 2024
-
ORGANIZATION Japan, US, Europe Trade Groups Urge Ishiba Govt to Scrap Off-Year Revisions
November 18, 2024
-
BUSINESS MSD Files Silgard 9 for Male Use in Japan
November 18, 2024
-
REGULATORY LDP Broadly OKs Draft Economic Package, Adds Text on FY2025 Revision
November 15, 2024
-
BUSINESS EMA Backs Leqembi after Re-Examination, but for Limited Use
November 15, 2024
-
REGULATORY MOF Stands Firm on Push for Full-Scale Off-Year Revision in FY2025
November 14, 2024
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…